The mechanisms of Alzheimer’s disease (AD) development are complex, and the detailed roles of neuroinflammation in AD still need to be elucidated. With various genetic and environmental risk factors, the accumulation of harmful amyloid plaques containing amyloid-β (Aβ) peptides is one of the main hallmarks of AD. Recent findings show that the innate immune protein interferon-induced transmembrane protein 3 (IFITM3) binds to γ-secretase and modulates Aβ production, providing a direct link between neuroinflammation, amyloidogenesis, and the pathogenesis of AD. In this review, we explore IFITM3-mediated modulation of γ-secretase complex activity and its pivotal role in AD pathology during neuroinflammation. Furthermore, we also provide an overview of the recent growing evidence connecting the roles of infection, the immune system, and AD pathogenesis.
AhmadiI, AfifipourA, SakhaeeF, et al.Impact of interferon-induced transmembrane protein 3 gene rs12252 polymorphism on COVID-19 mortality. Cytokine2022;157:155957.
2.
AlexanderC, LiT, HattoriY, et al.Hypoxia inducible factor-1alpha binds and activates gamma-secretase for Abeta production under hypoxia and cerebral hypoperfusion. Mol Psychiatry2022;27(10):4264–4273.
3.
BaileyCC, ZhongG, HuangIC, et al.IFITM-Family proteins: The cell’s first line of antiviral defense. Annu Rev Virol2014;1:261–283.
4.
BatemanRJ, SiemersER, MawuenyegaKG, et al.A gamma-secretase inhibitor decreases amyloid-beta production in the Central nervous system. Ann Neurol2009;66(1):48–54.
5.
BillingsLM, OddoS, GreenKN, et al.Intraneuronal abeta causes the onset of early alzheimer’s disease-related cognitive deficits in transgenic mice. Neuron2005;45(5):675–688.
6.
BolducDM, MontagnaDR, GuY, et al.Nicastrin functions to sterically hinder γ-secretase-substrate interactions driven by substrate transmembrane domain. Proc Natl Acad Sci U S A2016;113(5):E509–E518.
BrassAL, HuangIC, BenitaY, et al.The IFITM proteins mediate cellular resistance to influenza a H1N1 virus, West Nile virus, and dengue virus. Cell2009;139(7):1243–1254.
9.
BrouC, LogeatF, GuptaN, et al.A novel proteolytic cleavage involved in notch signaling: The role of the disintegrin-metalloprotease TACE. Mol Cell2000;5(2):207–216.
10.
ChenCK, WuYT, ChangYC. Association between chronic periodontitis and the risk of alzheimer’s disease: A retrospective, population-based, matched-cohort study. Alzheimers Res Ther2017;9(1):56.
11.
ChenF, HasegawaH, Schmitt-UlmsG, et al.TMP21 is a presenilin complex component that modulates γ-secretase but not ɛ-secretase activity. Nature2006;440(7088):1208–1212.
12.
ChenQ, SunL, ChenZJ. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat Immunol2016;17(10):1142–1149.
13.
ChenY, TangZ, TangZ, et al.Identification of core immune-related genes CTSK, C3, and IFITM1 for diagnosing Helicobacter pylori infection-associated gastric cancer through transcriptomic analysis. Int J Biol Macromol2025;287:138645.
14.
Cheng-HathawayPJ, Reed-GeaghanEG, JayTR, et al.The Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimer’s disease. Mol Neurodegener2018;13(1):29.
15.
ChungS, JeongJH, ParkJC, et al.Blockade of STING activation alleviates microglial dysfunction and a broad spectrum of Alzheimer’s disease pathologies. Exp Mol Med2024;56(9):1936–1951.
16.
CoricV, van DyckCH, SallowayS, et al.Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol2012;69(11):1430–1440.
17.
CrumpCJ, JohnsonDS, LiYM. Development and mechanism of gamma-secretase modulators for Alzheimer’s disease. Biochemistry2013;52(19):3197–3216.
18.
DanemanR, PratA. The blood-brain barrier. Cold Spring Harb Perspect Biol2015;7(1):a020412.
19.
De StrooperB, AnnaertW, CupersP, et al.A presenilin-1-dependent γ-secretase-like protease mediates release of notch intracellular domain. Nature1999;398(6727):518–522.
20.
De StrooperB, VassarR, GoldeT. The secretases: Enzymes with therapeutic potential in alzheimer disease. Nat Rev Neurol2010;6(2):99–107.
21.
DeczkowskaA, Keren-ShaulH, WeinerA, et al.Disease-Associated microglia: A universal immune sensor of neurodegeneration. Cell2018;173(5):1073–1081.
22.
DenzPJ, YountJS. IFITM3 variants point to a critical role in emergent virus infections. mBio2025;16(5):e03347-24.
23.
DiamondMS, FarzanM. The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat Rev Immunol2013;13(1):46–57.
24.
DominySS, LynchC, ErminiF, et al.Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv2019;5(1):eaau3333.
25.
DoodyRS, RamanR, FarlowM, et al.; Semagacestat Study Group. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med2013;369(4):341–350.
26.
DoveyHF, JohnV, AndersonJP, et al.Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem2001;76(1):173–181.
27.
EdbauerD, WinklerE, RegulaJT, et al.Reconstitution of gamma-secretase activity. Nat Cell Biol2003;5(5):486–488.
28.
EverittAR, ClareS, PertelT, et al.; MOSAIC Investigators. IFITM3 restricts the morbidity and mortality associated with influenza. Nature2012;484(7395):519–523.
29.
FaracoG, ParkL, ZhouP, et al.Hypertension enhances Aβ-induced neurovascular dysfunction, promotes β-secretase activity, and leads to amyloidogenic processing of APP. J Cereb Blood Flow Metab2016;36(1):241–252.
30.
FengY, WangS, YangD, et al.Inhibition of IFITM3 in cerebrovascular endothelium alleviates Alzheimer’s-related phenotypes. Alzheimers Dement2025;21(2):e14543.
31.
FriedmanRL, ManlySP, McMahonM, et al.Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. Cell1984;38(3):745–755.
32.
FukumoriA, SteinerH. Substrate recruitment of γ-secretase and mechanism of clinical presenilin mutations revealed by photoaffinity mapping. EMBO J2016;35(15):1628–1643.
33.
GaoC, JiangJ, TanY, et al.Microglia in neurodegenerative diseases: Mechanism and potential therapeutic targets. Signal Transduct Target Ther2023;8(1):359.
34.
GateD, SaligramaN, LeventhalO, et al.Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer’s disease. Nature2020;577(7790):399–404.
35.
GriciucA, TanziRE. The role of innate immune genes in Alzheimer’s disease. Curr Opin Neurol2021;34(2):228–236.
36.
GriciucA, PatelS, FedericoAN, et al.TREM2 acts downstream of CD33 in modulating microglial pathology in Alzheimer’s disease. Neuron2019;103(5):820–835.e7. e827.
37.
HaassC, KaetherC, ThinakaranG, et al.Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med2012;2(5):a006270.
38.
HakemFT, YfF, ArafaRK. Gamma secretase as an important drug target for management of Alzheimer’s disease: A comprehensive review. Curr Top Med Chem2024;24:109–127.
39.
HenekaMT, van der FlierWM, JessenF, et al.Neuroinflammation in alzheimer disease. Nat Rev Immunol2025;25(5):321–352.
40.
HickmanSE, AllisonEK, El KhouryJ. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer’s disease mice. J Neurosci2008;28(33):8354–8360.
41.
HoltzmanDM, MorrisJC, GoateAM. Alzheimer’s disease: The challenge of the second century. Sci Transl Med2011;3(77):77sr1.
42.
HuangTY, XuH. Bringing order out of chaos: Establishing an epistatic relationship between CD33 and TREM2. Neuron2019;103(5):747–749.
43.
HurJY, FrostGR, WuX, et al.The innate immunity protein IFITM3 modulates gamma-secretase in Alzheimer’s disease. Nature2020;586(7831):735–740.
44.
HurJY. Innate immunity protein IFITM3 in Alzheimer’s disease. DNA Cell Biol2021;40(11):1351–1355.
45.
HurJY. γ-secretase in Alzheimer’s disease. Exp Mol Med2022;54(4):433–446.
46.
IsoT, KedesL, HamamoriY. HES and HERP families: Multiple effectors of the notch signaling pathway. J Cell Physiol2003;194(3):237–255.
47.
IwatsuboT, OdakaA, SuzukiN, et al.Visualization of a beta 42(43) and a beta 40 in senile plaques with end-specific a beta monoclonals: Evidence that an initially deposited species is a beta 42(43). Neuron1994;13(1):45–53.
48.
JungS, HyunJ, NahJ, et al.SERP1 is an assembly regulator of γ-secretase in metabolic stress conditions. Sci Signal2020;13(623):eaax8949.
49.
KawaiT, AkiraS. Innate immune recognition of viral infection. Nat Immunol2006;7(2):131–137.
50.
Keren-ShaulH, SpinradA, WeinerA, et al.A unique microglia type associated with restricting development of Alzheimer’s disease. Cell2017;169(7):1276–1290.e17. e1217.
51.
KimberlyWT, LaVoieMJ, OstaszewskiBL, et al.Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, aph-1, and pen-2. Proc Natl Acad Sci U S A2003;100(11):6382–6387.
52.
KinneyJW, BemillerSM, MurtishawAS, et al.Inflammation as a Central mechanism in Alzheimer’s disease. Alzheimers Dement (N Y)2018;4:575–590.
53.
KnopmanDS, AmievaH, PetersenRC, et al.Alzheimer disease. Nat Rev Dis Primers2021;7(1):33.
54.
KongL, LiJ, GaoL, et al.Periodontitis-induced neuroinflammation triggers IFITM3-Aβ axis to cause Alzheimer’s disease-like pathology and cognitive decline. Alzheimers Res Ther2025;17(1):166.
55.
KumarDK, ChoiSH, WashicoskyKJ, et al.Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease. Sci Transl Med2016;8(340):340ra72.
56.
KupersteinI, BroersenK, BenilovaI, et al.Neurotoxicity of Alzheimer’s disease abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio. EMBO J2010;29(19):3408–3420.
57.
LachishM, FainsteinN, GanzT, et al.Failure of Alzheimer’s mice brain resident neural precursor cells in supporting microglia-mediated amyloid β clearance. Cells2022;11(5):876.
58.
LaiMT, ChenE, CrouthamelMC, et al.Presenilin-1 and presenilin-2 exhibit distinct yet overlapping gamma-secretase activities. J Biol Chem2003;278(25):22475–22481.
LiY, WeiL, HeL, et al.Interferon-induced transmembrane protein 3 gene polymorphisms are associated with COVID-19 susceptibility and severity: A meta-analysis. J Infect2022;84(6):825–833.
61.
LiYM, XuM, LaiMT, et al.Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature2000;405(6787):689–694.
62.
LoveS, MinersJS. Cerebrovascular disease in ageing and Alzheimer’s disease. Acta Neuropathol2016;131(5):645–658.
63.
LvY, ZouW, LiL, et al.IFITM2 modulates endocytosis maintaining neural stem cells in developing neocortex. Adv Sci (Weinh)2025;12(17):e2501593.
64.
McConnellHL, MishraA. Cells of the blood-brain barrier: An overview of the neurovascular unit in health and disease. Methods Mol Biol2022;2492:3–24.
65.
Miguel-ÁlvarezM, Santos-LozanoA, Sanchis-GomarF, et al.Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer’s disease: A systematic review and meta-analysis of treatment effect. Drugs Aging2015;32(2):139–147.
66.
NarayanaSK, HelbigKJ, McCartneyEM, et al.The interferon-induced transmembrane proteins, IFITM1, IFITM2, and IFITM3 inhibit hepatitis C virus entry. J Biol Chem2015;290(43):25946–25959.
67.
NguyenAT, WangK, HuG, et al.APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer’s disease. Acta Neuropathol2020;140(4):477–493.
68.
NiX, PanY, LiuX, et al.Neuroimmune regulation of IFITM3 via γ-secretase in astrocytes during cerebral ischemia-reperfusion. Biochim Biophys Acta Mol Basis Dis2025;1871(4):167733.
69.
NordvallG, LundkvistJ, SandinJ. Gamma-secretase modulators: A promising route for the treatment of Alzheimer’s disease. Front Mol Neurosci2023;16:1279740.
70.
PerlDP. Neuropathology of Alzheimer’s disease. Mt Sinai J Med2010;77(1):32–42.
71.
PetitD, HitzenbergerM, KochM, et al.Enzyme-substrate interface targeting by imidazole-based γ-secretase modulators activates γ-secretase and stabilizes its interaction with APP. EMBO J2022;41(21):e111084.
72.
RansohoffRM, BrownMA. Innate immunity in the Central nervous system. J Clin Invest2012;122(4):1164–1171.
73.
SastreM, GentlemanSM. NSAIDs: How they work and their prospects as therapeutics in Alzheimer’s disease. Front Aging Neurosci2010;2:20.
74.
SelkoeDJ, HardyJ. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med2016;8(6):595–608.
75.
SelkoeDJ. Alzheimer’s disease: Genes, proteins, and therapy. Physiol Rev2001;81(2):741–766.
76.
Serrano-PozoA, MielkeML, Gómez-IslaT, et al.Reactive glia not only associates with plaques but also parallels tangles in Alzheimer’s disease. Am J Pathol2011;179(3):1373–1384.
77.
SimicG, Babic LekoM, WrayS, et al.Tau protein hyperphosphorylation and aggregation in Alzheimer’s disease and other tauopathies, and possible neuroprotective strategies. Biomolecules2016;6(1):6.
78.
St George-HyslopPH. Piecing together Alzheimer’s. Sci Am2000;283(6):76–83.
79.
SteinerH, WinklerE, EdbauerD, et al.PEN-2 is an integral component of the gamma-secretase complex required for coordinated expression of presenilin and nicastrin. J Biol Chem2002;277(42):39062–39065.
80.
StruhlG, AdachiA. Requirements for presenilin-dependent cleavage of notch and other transmembrane proteins. Mol Cell2000;6(3):625–636.
81.
TakamiM, NagashimaY, SanoY, et al.gamma-Secretase: Successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci2009;29(41):13042–13052.
82.
TakeuchiO, AkiraS. Pattern recognition receptors and inflammation. Cell2010;140(6):805–820.
83.
ThinakaranG, BorcheltDR, LeeMK, et al.Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron1996;17(1):181–190.
84.
van de HaarHJ, JansenJFA, van OschMJP, et al.Neurovascular unit impairment in early Alzheimer’s disease measured with magnetic resonance imaging. Neurobiol Aging2016;45:190–196.
85.
VassarR, BennettBD, Babu-KhanS, et al.Beta-secretase cleavage of alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science1999;286(5440):735–741.
86.
VillaJC, ChiuD, BrandesAH, et al.Nontranscriptional role of hif-1alpha in activation of gamma-secretase and notch signaling in breast cancer. Cell Rep2014;8(4):1077–1092.
87.
WakimLM, GuptaN, MinternJD, et al.Enhanced survival of lung tissue-resident memory CD8(+) T cells during infection with influenza virus due to selective expression of IFITM3. Nat Immunol2013;14(3):238–245.
88.
WaltersA, PhillipsE, ZhengR, et al.Evidence for neuroinflammation in alzheimer’s disease. Prog Neurol Psychiatry2016;20(5):25–31.
89.
WeggenS, EriksenJL, DasP, et al.A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature2001;414(6860):212–216.
90.
WolfeMS, XiaW, OstaszewskiBL, et al.Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature1999;398(6727):513–517.
91.
WuZ, TangW, IbrahimF, et al.Aβ induces neuroinflammation and microglial M1 polarization via cGAS-STING-IFITM3 signaling pathway in BV-2 cells. Neurochem Res2023;48(9):2881–2894.
92.
YanezDC, RossS, CromptonT. The IFITM protein family in adaptive immunity. Immunology2020;159(4):365–372.
93.
YangY, DingT, CongY, et al.Interferon-induced transmembrane protein-1 competitively blocks ephrin receptor A2-mediated Epstein-Barr virus entry into epithelial cells. Nat Microbiol2024;9(5):1256–1270.
94.
ZhangY-H, ZhaoY, LiN, et al.Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals. Nat Commun2013;4:1418.
95.
ZhaoM, MaG, YanX, et al.Microbial infection promotes amyloid pathology in a mouse model of Alzheimer’s disease via modulating γ-secretase. Mol Psychiatry2024;29(5):1491–1500.
